Trial Profile
A European Multi-Center, Multi-Country, Post-Authorisation, Observational Study (Registry) Of Patients With Hereditary Angioedema (HAE) Who Are Administered CINRYZE® (C1 Inhibitor [Human]) For The Treatment Or Prevention Of HAE Attacks
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors Shire
- 05 Oct 2016 Status changed from active, no longer recruiting to completed.
- 22 Mar 2016 New trial record
- 07 Mar 2016 Interim results (n=45) presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology